KRMD 8-K
KORU Medical Systems, Inc. (KRMD)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area
code (
______________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
ITEM 4.01 Changes in Registrant’s Certifying Accountant.
(a) On June 3, 2024, the Audit Committee (the “Audit Committee”) of the board of directors of the Company approved the dismissal of McGrail Merkel Quinn & Associates, P.C. (“MMQ”) as the Company’s independent registered public accounting firm, effective immediately.
The reports of MMQ on the Company’s financial statements for each of the two fiscal years ended December 31, 2023 and December 31, 2022 did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles.
In connection with the audits of the Company’s financial statements for each of the two fiscal years ended December 31, 2023 and December 31, 2022, and in the subsequent interim period through June 3, 2024, there were no “disagreements” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) between the Company and MMQ on any matters of accounting principles or practices, financial statement disclosure or auditing scope and procedures which, if not resolved to the satisfaction of MMQ, would have caused MMQ to make reference to the subject matter of the disagreement in their reports.
The Company provided MMQ with a copy of the disclosures it is making in this Current Report on Form 8-K and requested that MMQ furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements contained herein.
A copy of MMQ’s letter, dated June 3, 2024, is filed as Exhibit 16.1 to this Current Report on Form 8-K.
(b) On June 3, 2024, the Audit Committee approved, on behalf of the Company, the engagement of Cherry Bekaert LLP (“Cherry Bekaert”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
During the years ended December 31, 2023 and 2022, and the subsequent interim period through June 3, 2024, neither the Company nor anyone on its behalf consulted with Cherry Bekaert regarding either (i) the application of accounting principles to a specific transaction, completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that Cherry Bekaert concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
As described in Item 4.01 of this Report, the following exhibit is filed as part of this Current Report on Form 8-K:
| Exhibit No. | Description |
| 16.1 | Letter dated June 3, 2024 from McGrail Merkel Quinn & Associates, P.C. to the Securities and Exchange Commission confirming the disclosures contained in Item 4.01 of this report on Form 8-K |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KORU Medical Systems, Inc. (Registrant) | ||
| Date: June 3, 2024 | By: | /s/ Linda Tharby |
| Linda Tharby President and Chief Executive Officer | ||
- 3 -
EXHIBIT 16.1
June 3, 2024
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Commissioners:
We have read the Company’s statements included under Item 4.01(a) of its Current Report on Form 8-K dated June 3, 2024 (the “Form 8-K”), and we agree with such statements.
Very truly yours,
/s/ McGrail Merkel Quinn & Associates, P.C.
Scranton, Pennsylvania